Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 1,
Disease:Adenocarcinoma
Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-GDE1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
MIR16 also known as microRNA-16 is a small non-coding RNA molecule typically around 22 nucleotides in length. This microRNA engages in the post-transcriptional regulation of gene expression impacting various mRNAs by binding and either degrading them or inhibiting their translation. MIR16 is expressed in numerous human tissues including the lungs heart and spleen indicating its broad functional significance in the body.
Biological function summary
MIR16 regulates cell cycle progression and apoptosis playing a role in maintaining cellular homeostasis. It is part of the microRNA-induced silencing complex (RISC) enabling it to mediate gene silencing efficiently. By influencing the expression of genes involved in the cell cycle MIR16 helps control cell proliferation and programmed cell death which are important processes for normal cellular function and response to stress.
Pathways
MIR16 is involved in the cell cycle and apoptosis signaling pathways. It interacts with key proteins such as cyclin D1 and Bcl-2 which are essential for cell cycle regulation and apoptosis respectively. By modulating these pathways MIR16 contributes to maintaining the balance between cell survival and death which is necessary to prevent abnormal cell growth.
MIR16 has connections to cancer and cardiovascular diseases. Aberrant expression of MIR16 can lead to uncontrolled cell proliferation linking it to cancer progression particularly in chronic lymphocytic leukemia where it shows reduced expression. Moreover its role in regulating apoptosis implicates MIR16 in cardiovascular diseases where its dysregulation can impact heart function. The interaction with proteins such as Bcl-2 in these conditions highlights its potential as a therapeutic target in disease management.
